Agilent Technologies (NYSE:A – Get Free Report) and Sanuwave Health (NASDAQ:SNWV – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Insider & Institutional Ownership
42.5% of Sanuwave Health shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Agilent Technologies and Sanuwave Health”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agilent Technologies | $6.95 billion | 5.49 | $1.30 billion | $4.98 | 27.12 |
| Sanuwave Health | $44.05 million | 2.95 | $11.81 million | $0.33 | 45.73 |
Agilent Technologies has higher revenue and earnings than Sanuwave Health. Agilent Technologies is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Agilent Technologies has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Sanuwave Health has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Profitability
This table compares Agilent Technologies and Sanuwave Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agilent Technologies | 19.55% | 24.33% | 12.99% |
| Sanuwave Health | 35.96% | -450.56% | 44.87% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Agilent Technologies and Sanuwave Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agilent Technologies | 0 | 2 | 12 | 2 | 3.00 |
| Sanuwave Health | 1 | 1 | 1 | 1 | 2.50 |
Agilent Technologies currently has a consensus target price of $162.79, indicating a potential upside of 20.55%. Sanuwave Health has a consensus target price of $51.00, indicating a potential upside of 237.97%. Given Sanuwave Health’s higher possible upside, analysts plainly believe Sanuwave Health is more favorable than Agilent Technologies.
Summary
Agilent Technologies beats Sanuwave Health on 8 of the 15 factors compared between the two stocks.
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
About Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
